HEMOSTATIC PARTICLES BASED ON CHITOSAN WITH EMBEDDED ACTIVE SUBSTANCES AND METHOD FOR PRODUCTION THEREOF Russian patent published in 2024 - IPC A61K31/722 A61L15/16 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to hemostatic particles based on chitosan with embedded active substances, characterized by that they have the shape of spherical particles with specific surface area from 100 to 1,500 m²/g, porosity from 90.0 to 99.9% with mesopore size of 1–30 nm to 0.5–2.5 cm³/g, contain drugs lidocaine hydrochloride and/or erythromycin in an amorphous state, also relates to a method of producing hemostatic particles based on chitosan with embedded active substances, which consists in the fact that a solution of chitosan in 0.1–0.2M acetic acid is instilled into an aqueous solution of an alkali with concentration of 0.1–4M and held for 24 hours, formed particles of chitosan gel are washed with distilled water to pH 7–8, the upper aqueous layer is separated, isopropyl alcohol with increasing concentration from 10 to 99.8 wt.% and held for 3–4 hours, then adding lidocaine hydrochloride and/or erythromycin and drying by supercritical drying at temperature of 40 °C, pressure from 120 to 140 atm and carbon dioxide consumption of 0.2 kg/h, and also relates to a method of producing chitosan-based haemostatic particles with embedded active substances, which consists in the fact that a solution of chitosan in 0.1–0.2M acetic acid is instilled into an aqueous solution of an alkali with concentration of 0.1–4M and held for 24 hours, formed particles of chitosan gel are washed with distilled water to pH 7–8, the upper aqueous layer is separated, isopropyl alcohol with increasing concentration from 10 to 99.8 wt.%, held for 3–4 hours and dried by supercritical drying at temperature of 40 °C, pressure from 120 to 140 atm and carbon dioxide consumption of 0.2 kg/h, then supercritical adsorption of lidocaine hydrochloride and/or erythromycin is carried out at pressure of 180 atm or 200 atm and temperature of 40 °C, 60 °C or 95 °C in ratio of 1:1 mass of chitosan aerogel to mass of active substance.

EFFECT: group of inventions provides creation of a highly effective wound healing and haemostatic agent based on chitosan, having high specific surface area, porosity and sorption capacity and small pore size.

3 cl, 8 ex